AVEO Pharmaceuticals (AVEO) was Initiated by Piper Jaffray to “Overweight” and the brokerage firm has set the Price Target at $1.70. Piper Jaffray advised their investors in a research report released on May 19, 2016.
Many Wall Street Analysts have commented on AVEO Pharmaceuticals. FBR Capital Initiated AVEO Pharmaceuticals on Mar 30, 2016 to “Outperform”, Price Target of the shares are set at $3.
AVEO Pharmaceuticals closed down -0.0101 points or -1.13% at $0.8799 with 1,82,914 shares getting traded on Monday. Post opening the session at $0.88, the shares hit an intraday low of $0.86 and an intraday high of $0.88 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Jan 20, 2015, Matthew D Dallas (VP, Finance) sold 3,075 shares at $0.82 per share price. According to the SEC, on Jan 8, 2015, Jeno Gyuris (SVP, Chief Scientific Officer) sold 4,484 shares at $0.80 per share price. On Jan 8, 2015, Joseph Vittiglio (SVP, General Counsel) sold 4,484 shares at $0.80 per share price, according to the Form-4 filing with the securities and exchange commission.
AVEO Pharmaceuticals Inc. (AVEO) is a biopharmaceutical company. The Company’s platform has delivered insights into cancer and related disease. The Company’s Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Company’s product candidates include AV203 Ficlatuzumab Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).